Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.65 |
| ▸ | DRD3 | P35462 | 5/20 | 0.65 |
| ▸ | DRD2 | P14416 | 4/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11622067 | 0.99 | KCNH2 (0.64) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL4711836 | 0.82 | SLC6A2 (0.68) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL13201897 | 0.79 | DRD3 (1.00) | KCNH2DRD3DRD2CYP1A2CYP3A4 | |
| SCHEMBL4713248 | 0.76 | SLC6A2 (0.41) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL4712815 | 0.75 | SLC6A2 (0.62) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| Bicifadine SCHEMBL38793 | 0.74 | SLC6A2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| Bicifadine SCHEMBL6003632 | 0.74 | SLC6A2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL11083508 | 0.74 | SLC6A2 (0.59) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL4716048 | 0.72 | SLC6A2 (0.62) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL4710604 | 0.72 | SLC6A2 (0.62) | KCNH2DRD3DRD2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2007-01-25 | — | — | US | claimed |
| EP-1904059-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007013936-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | AVPR1B, AVPR2, AVPR1A | KCNH2 242/4885DRD3 603/4885DRD2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.